Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2020

View Archived Issues

FDA clears IND application for first-in-human trial of IO-202

FDA approves Tauvid for PET imaging in patients being evaluated for AD

Phenotype detection platform screens for new PD drugs

Tumor types have distinct microbiomes

New alcohol risk genes in Caucasians

A series of benzimidazolones causing rapid degradation of BCL6 as potential therapeutics for DLBCL

New inhibitors of the minichromosomal maintenance protein with potential for the treatment of NSCLC

LMP2 inhibition shows therapeutic potential in AD by protecting against neuroinflammation

Edgewise Therapeutics presents new myosin inhibitors

New JAK-2 inhibitors identified at the Dana-Farber Cancer Institute

Rudong Ringene Pharmaceuticals patents PTPN11 inhibitors

New histone deacetylase inhibitors discovered at Merck & Co.

Genentech and Roche synthesize new RAS protein inhibitors

Novus reports topline phase IIa data on OP-0201 in acute otitis media

Gilead reports phase III data on remdesivir in moderate COVID-19 pneumonia

FDA clears Opko to begin phase II trial of Rayaldee for mild to moderate COVID-19

Ocugen discontinues phase III trial of OCU-300 for ocular graft-versus-host disease

Interim phase Ib data with ALRN-6924 show chemoprotective effect

Avelumab does not show activity in recurrent osteosarcoma trial

FDA approves Brilinta to reduce first heart attack in patients with coronary artery disease

Mesothelin-targeting CAR MCY-M11 appears to be safe in phase I trial

Nicox's NCX-470 enters phase III development

CTI enrolling patients in phase III PREVENT trial of pacritinib in severe COVID-19

Olokizumab obtains first approval in Russia

Phase III study of sulopenem in cUTI does not meet primary endpoint

FDA approves Taltz for active nonradiographic axial spondyloarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...